The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Targeting myeloid derived suppressor cells: Phase 0/1 trial of low dose capecitabine + bevacizumab in patients with recurrent glioblastoma.
 
David M. Peereboom
Research Funding - Mylan (Inst)
 
Justin D. Lathia
Research Funding - FORMA Therapeutics; Syntrix Biosystems
 
Tyler Alban
No Relationships to Disclose
 
Maksim Sinyuk
No Relationships to Disclose
 
Manmeet Singh Ahluwalia
Honoraria - Elsevier; Itamar Medical (I); Prime Oncology
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Incyte; Monteris Medical
Research Funding - Boehringer Ingelheim; Lilly/ImClone; Novartis; Novocure; Spectrum Pharmaceuticals; TRACON Pharma
 
Alireza Mohammad Mohammadi
No Relationships to Disclose
 
Cathy J. Brewer
No Relationships to Disclose
 
Michael A. Vogelbaum
Stock and Other Ownership Interests - Johnson & Johnson
Research Funding - Infusion Therapeutics; Tocagen
Patents, Royalties, Other Intellectual Property - Infusion Therapeutics